Top 20 pharmaceutical companies by revenues in 2020
Updated: Oct 17
TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 202O
The other big biopharmaceutical companies are Teva, Takeda, Baxter, Mylan, and Merck group.
JOHNSON AND JOHNSON
Q1 RESULTS OF JOHNSON AND JOHNSON
Johnson and Johnson announced sales of $20.7 billion in the first quarter of 2020, showing an operational growth of 3.3%. The sales from pharmaceuticals accounted for $11.13 billion, with an increase of 8.7%. However, the company has reported a decline in the sales of medical devices.
Stelara revenue grew by 10.2% (indicated for immune-mediated inflammatory diseases). Other growth drivers were Darzalex (indicated for multiple myeloma), Imbruvica (indicated for B-cell malignancies), Ingega (indicated for schizophrenia), Erleada (indicated for prostate cancer), Opsumit (indicated for pulmonary arterial hypertension), Tremfya (indicated for psoriasis), and Prezista (indicated for HIV infection).
Q2 SALES OF JOHNSON AND JOHNSON
Johnson and Johnson announced sales of $ 18.34 billion in the second quarter of 2020. The sales were reduced by 10.8% compared to the sales of 2019 ($ 20.56 bn). COVID19 pandemic impacted sales.
Pharmaceutical sales grew by 3.9%. The sales were driven by Stelara, Darzalex, Imbruvica, Erleada, Tremfya, Uptravi, and Opsumit. The sales were impacted by the biosimilar competition of Remicade and generics of Velcade and Zytiga.
The sales of medical devices were declined by 32.5%, and consumer health decreased by 3.4%.
Q3 SALES OF JOHNSON AND JOHNSON
Johnson and Johnson announced positive results in Q3 of 2020. The company has announced an increase in sales of 1.7%. The company has reported $21.08 billion sales in Q3 of 2020 compared to the $20.73 billion in Q3 of 2019.
The pharmaceutical segment sales were increased by 5.0%. Pharmaceutical sales were $11.42 billion in Q3 of 2020 compared to $10.88 billion in Q3 2019. The sales were primarily driven by Stelara ($1.31 billion), Trevicta ($0.93 bi9llion), Darzalex ($ 1.1 billion), and Imbruvica ($ 1.03 billion).
Q1 RESULTS OF ROCHE
Roche reported sales of $16.3 billion in the first quarter of 2020. The sales of pharmaceuticals were increased by 7%; the growth drivers were Tecentriq, Hemlibra, Ocrevus, and Perjeta.
The sales in the US grew by 3%, and in Europe, sales increased by 14% because of the strong demand for Tecentriq, Ocrevus, Perjeta, Hemlibra, Actemra/RoActemra, and Kadcyla. In Japan, sales grew by 3%.
The sales of diagnostics were increased by 5%.
Q2 RESULTS OF ROCHE
Roche announced that its second-quarter sales were significantly impacted because of COVID19. There was a 4% decline in sales in the second quarter. In May, the sales were dropped by 15%; however, they increased by 3% in June.
Avastin biosimilars are expected to enter the European market in the second half of 2020. A drop of 18% of sales in the first half of 2020 was reported due to biosimilars competition in the US and Japan.
In the first six months, Ocrevus ($ 2.26 bn) sales increased by 15%, Perjeta ($2 bn) sales increased by 17%, Tecentriq ($1.4 bn) sales increased by 75%, and Hemlibra ($1.2 bn) sales increased by 94%.
Q1 RESULTS OF PFIZER
Pfizer revenues were dropped by 7% because of the decrease in the sales of consumer products. The biopharma revenues were increased by 12%, primarily because of Eliquis, Vyndaqel, Ibrance, and Inlyta.
Q2 RESULTS OF PFIZER
In the second quarter, the sales were dropped by 9%, 6% operational growth was reported from biopharmaceuticals. The sales in the second quarter were driven by Vyndaqel/Vyndamax, Eliquis, Ibrance, Inlyta, and Xtandi.
The H1 sales were dropped by 10%.
Q1 RESULTS OF NOVARTIS
Novartis reported strong performance in Q1, with sales increased by 13%. The sales were primarily driven by Entresto USD 569 million, Zolgensma USD 170 million, Cosentyx USD 930 million, Kisqali USD 161 million, and Piqray USD 74 million.
Q2 RESULTS OF NOVARTIS
Novartis announced that net sales were decreased by 1%. COVID19 pandemic has impacted sales, especially ophthalmology products.
For pipeline, market overview, and market access reports (syndicate and customized) please write to firstname.lastname@example.org
For all syndicate reports: Click here